What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

Weightloss in Menopause

Susan Brian

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Tirzepatide Updates

Diana Isaacs

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

New Research: Side Effect of GLP1

Susan Brian

Cardio-Renal Syndrome Management: What Are the Key Factors That Impa…

Patricia Kao

Tirzepatide for Type 2 Diabetes

Diana Isaacs

GIP Antagonism or Agonism?

Jens Juul Holst